GSK-Pfizer deal prompts New Zealand regulator's preliminary remarks
MLex Summary: The impact of GlaxoSmithKline's plans to acquire Pfizer's consumer healthcare business will be vetted by New Zealand's competition regulator. The New Zealand Commerce Commission will review the possible affect...To view the full article, register now.
Already a subscriber? Click here to view full article